Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Large Increase in Short Interest

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) saw a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 455,197 shares, a growth of 156.9% from the June 15th total of 177,209 shares. Based on an average daily volume of 444,373 shares, the short-interest ratio is currently 1.0 days. Approximately 46.8% of the shares of the company are sold short.

Insider Activity

In other Bluejay Diagnostics news, major shareholder Financial Lp Hrt purchased 64,047 shares of Bluejay Diagnostics stock in a transaction dated Thursday, July 9th. The stock was acquired at an average cost of $1.51 per share, with a total value of $96,710.97. Following the acquisition, the insider directly owned 126,993 shares of the company’s stock, valued at $191,759.43. This represents a 101.75% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics as of its most recent SEC filing. 18.47% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Bluejay Diagnostics currently has an average rating of “Sell”.

Bluejay Diagnostics Price Performance

Bluejay Diagnostics stock traded up $0.10 during mid-day trading on Wednesday, reaching $1.34. The company had a trading volume of 3,834,374 shares, compared to its average volume of 1,935,806. The stock’s 50-day simple moving average is $2.67 and its 200-day simple moving average is $2.47. Bluejay Diagnostics has a 1 year low of $1.03 and a 1 year high of $16.68. The company has a market capitalization of $1.39 million, a P/E ratio of -0.12 and a beta of 0.88.

Bluejay Diagnostics (NASDAQ:BJDX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share for the quarter.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.